公开(公告)号：US11771704B1

公开(公告)日：2023-10-03

申请号：US18175605

申请日：2023-02-28

申请人： Woolsey Pharmaceuticals, Inc.

发明人： Thomas MacAllister ,  Sven Jacobson

IPC分类号： A61K31/5513 ,  A61K9/00 ,  A61P25/28

CPC分类号： A61K31/5513 ,  A61K9/0053 ,  A61P25/28

摘要： Disclosed are methods of treating patients with AD using a rho kinase inhibitor. A preferred rho kinase inhibitor used according to the invention is fasudil, which is typically administered orally in a total daily dose of 70-140 mg. A preferred dosing regimen involves administering the daily dose in three equal portions throughout the day. Preferred methods continue for more than one month and typically at least 2 or 3 months. Some preferred methods do not treat mild cognitive impairment and patients have and MMSE score of≤23 and/or a CDR-SOB score of≥4.5.

公开(公告)号：US11642352B2

公开(公告)日：2023-05-09

申请号：US17144802

申请日：2021-01-08

申请人： WOOLSEY PHARMACEUTICALS, INC.

发明人： Thomas MacAllister ,  Sven Jacobson

IPC分类号： A61K31/551 ,  A61P25/28

CPC分类号： A61K31/551 ,  A61P25/28

摘要： The invention is based on the discovery that rho kinase inhibitors can be used to treat proteinopathy associated wandering. A number of degenerative neurological diseases are thought to be caused, at least in part, by the formation of protein aggregates that cause neurotoxicity and progressive decline in function. The inventive methods related to the use of rho kinase inhibitors in the treatment of patients with proteinopathy-associated wandering. The patients may be suffering from Huntington's disease, a traumatic brain injury, autism spectrum disorder, Down syndrome or a proteinopathy-associated dementia, such as Alzheimer disease or frontotemporal dementia.

公开(公告)号：US11311553B1

公开(公告)日：2022-04-26

申请号：US17145084

申请日：2021-01-08

申请人： Woolsey Pharmaceuticals, Inc.

发明人： Thomas MacAllister ,  Sven Jacobson

IPC分类号： A61K31/551

摘要： The present invention relates to the treatment patient with a 4-repeat (4R) tauopathy using a therapeutically effect amount of a rho kinase inhibitor. One preferred inhibitor is fasudil and preferred methods involve the daily oral administration of between 20 and 250 mg of fasudil. Preferred 4R tauopathies treatable according to the invention include progressive supranuclear palsy with Richardson syndrome (PSP-RS) and corticobasal syndrome with probable sporadic corticobasal degeneration.

公开(公告)号：US11865119B2

公开(公告)日：2024-01-09

申请号：US18177188

申请日：2023-03-02

申请人： Woolsey Pharmaceuticals, Inc.

发明人： Thomas MacAllister ,  Sven Jacobson

IPC分类号： A61K31/5513 ,  A61P25/28 ,  A61K9/00

CPC分类号： A61K31/5513 ,  A61P25/28 ,  A61K9/0053

摘要： The invention is based on the discovery that rho kinase inhibitors, particularly fasudil can be used to treat agitation/anxiety in dementia patients, particularly Alzheimer's disease patients. Fasudil treatment of Alzheimer's patients resulted in improvements in agitation that are orders of magnitude to that observed with other potential therapeutic agents.

公开(公告)号：US11666583B2

公开(公告)日：2023-06-06

申请号：US17144861

申请日：2021-01-08

申请人： WOOLSEY PHARMACEUTICALS, INC.

发明人： Thomas Macallister ,  Sven Jacobson

IPC分类号： A61K31/551 ,  A61P25/28

CPC分类号： A61K31/551 ,  A61P25/28

摘要： The invention is based on the discovery that rho kinase inhibitors can be used to treat certain dementia-associated wandering. The inventive methods relate to the use of rho kinase inhibitors in the treatment of patients with cortical dementia-associated wandering. Preferred aspects of the invention contemplate treating wandering due to cortical vascular dementia and wandering due to dementia where the patient is a persistent wanderer and/or where the patient does not display a wayfinding defect.

公开(公告)号：US11779588B2

公开(公告)日：2023-10-10

申请号：US17502507

申请日：2021-10-15

申请人： Woolsey Pharmaceuticals, Inc.

发明人： Thomas MacAllister ,  Sven Jacobson

IPC分类号： A61K31/551 ,  A61K31/472 ,  A61K31/4725 ,  A61P25/28 ,  C07D401/12

CPC分类号： A61K31/551 ,  A61P25/28

摘要： The present invention relates to the treatment of a sporadic ALS patient with oral fausdil at a dose of 180-240 mg/day. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.